Table 2.

Summary of Published in Vivo Applications of Anti-MDM2 Oligonucleotides

Tumor TypeCell LineAnimal Modelp53 Gene StatusOligonucleotide, Amount, ScheduleDrugsEffects of CotreatmentReferences
Prostate cancerDU-145, PC-3MiceNDaAnti-MDM2-MBO, 25 mg/kg/day, 4 × 5 days/wkIrinotecan, paclitaxel, rituxanSynergistic effect (+ irinotecan) slightly increased activity (+ paclitaxel, rituxan)(56)
Colon cancerLS174TMiceWild-typeAnti-MDM2-MBO, 20 mg/kg/day, 5 days/wk10-Hydroxy-camphothecin, 5-fluorouracilSynergistically or additive therapeutic effects(46, 57)
DLD-1Mutant
Glioblastoma multiformeU87-MGMiceWild-typeAnti-MDM2-MBO, 25 mg/kg/day, 5 days/wkIrinotecan, paclitaxelInhibition of tumor growth, 39- and 63-fold activity of irinotecan and paclitaxel(48)
RhabdomyosarcomaRDRatMutantAnti-MDM2-MBO, 100 μg continuously over 1 wkSignificantly reduced tumor growth, decreased mutant p53 levels(51)
Breast cancerMCF-7MiceWild-typeAnti-MDM2-MBO, 25 mg/kg/day, 3 × 5 days/wkIrinotecan, paclitaxel, 5-fluorouracilSynergistically or additive therapeutic effects(47)
MDA-MB-468Mutant
Colon cancerGEOMiceNDAnti-MDM2-MBO, 10 mg/kg/day, 2 × 5 days/wkCisplatin, topotecanPotentiation of effects of cisplatin, topotecan(45)
OsteosarcomaSJSAMiceNDAnti-MDM2-MBO, 25 mg/kg/day10-Hydroxy-camphothecin, AdriamycinSynergistic effect of cotreatmant(44)
ChoriocarcinomaJARMiceNDAnti-MDM2-MBO, 25 mg/kg/day10-Hydroxy-camphothecin, AdriamycinSynergistic effect of cotreatmant(44)
  • a ND, not determined